We are honored to have participated in Rakuten Medical's latest funding round alongside TaiAx Fund, Nexus CVC, OEP Group, Daiwa Securities, Mitsui Sumitomo Insurance, Sumitomo Mitsui Banking and other investors. We would also like to extend our sincere congratulations to the Rakuten Medical team for successfully raising USD 100 million (approximately NTD 3.14 billion) in their Series F financing, thanks to the strong recognition of their groundbreaking Alluminox™ platform and exceptional cancer treatment approach.
We look forward to seeing Rakuten Medical accelerate the global rollout of this innovative and safe therapeutic technology, benefiting more patients around the world who are fighting cancer.
https://rakuten-med.com/us/news/press-releases/2026/01/07/7929/
https://udn.com/news/story/7241/9250963
